Long-Acting Injectable Aqueous Suspensions—Summary From an AAPS Workshop

Burgess DJ, Wright JC. An introduction to long acting injections and implants. In: In Burgess DJ, Wright JC, editors. long acting injections and implants. Springer; 2012. p. 1–9.

Google Scholar 

Kipp JE. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm. 2004;284:109–22.

Article  CAS  PubMed  Google Scholar 

Rhee YS, Park CW, Deluca PP, Mansour HM. Sustained-release injectable drug delivery: a review of current and future systems. PharmTechnol. 2010;s6:8–13.

Google Scholar 

Maresova P, Javanmardi E, Barakovic S, BarakovicHusic J, Tomsone S, Krejcar O, Kuca K. Consequences of chronic diseases and other limitations associated with old age - a scoping review. BMC Public Health. 2019;19:1431.

Article  PubMed  PubMed Central  Google Scholar 

Brissos S, Veguilla MR, Taylor D, Balanzá-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014;4:198–219.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Remenar JF. Making the leap from daily oral dosing to long-acting injectables: lessons from the antipsychotics. Mol Pharm. 2014;11:1739–49.

Article  CAS  PubMed  Google Scholar 

Rubio JM, Schoretsanitis G, John M, Tiihonen J, Taipale H, Guinart D, Malhotra AK, Correll CU, Kane JM. Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. Lancet Psychiatry. 2020;7:749–61.

Article  PubMed  Google Scholar 

Morris MT, Tarpada SP. Long-acting injectable paliperidone palmitate: A review of efficacy and safety. Psychopharmacol Bull. 2017;47:42–52.

PubMed  PubMed Central  Google Scholar 

Owen A, Rannard S. Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy. Adv Drug Deliv Rev. 2016;103:144–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 2004;3:785–96.

Article  CAS  PubMed  Google Scholar 

Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Therapeut. 2001;23:1296–310.

Article  CAS  Google Scholar 

Coleman CI, Limone B, Sobieraj DM, Lee S, Roberts MS, Kaur R, Alam T. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18:527–39.

PubMed  Google Scholar 

Coleman CI, Roberts MS, Sobieraj DM, Lee S, Alam T, Kaur R. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin. 2012;28:669–80.

Article  CAS  PubMed  Google Scholar 

Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15:e22-33.

PubMed  Google Scholar 

Leenen FH, Wilson TW, Bolli P, Larochelle P, Myers M, Handa SP, Boileau G, Tanner J. Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring. Can J Cardiol. 1997;13:914–20.

CAS  PubMed  Google Scholar 

Eberlin M, Otto G, Krämer I. Increased medication compliance of liver transplant patients switched from a twice-daily to a once-daily tacrolimus-based immunosuppressive regimen. Transplant Proc. 2013;45:2314–20.

Article  CAS  PubMed  Google Scholar 

Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55:886–91.

Article  PubMed  Google Scholar 

Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006;67:453–60.

Article  PubMed  Google Scholar 

Sajatovic M, Levin J, Ramirez LF, Hahn DY, Tatsuoka C, Bialko CS, Cassidy KA, Fuentes-Casiano E, Williams TD. Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2013;74:1249–55.

Article  PubMed  PubMed Central  Google Scholar 

Morrissette DA, Stahl SM. Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment. CNS Spectr. 2012;17(Suppl 1):10–21.

Article  PubMed  Google Scholar 

Okoli CTC, Kappi A, Wang T, Makowski A, Cooley AT. The effect of long-acting injectable antipsychotic medications compared with oral antipsychotic medications among people with schizophrenia: A systematic review and meta-analysis. Int J Ment Health Nurs. 2022;31:469–535.

Article  PubMed  Google Scholar 

Hirsch SR, Gaind R, Rohde PD, Stevens BC, Wing JK. Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry. Br Med J. 1973;1:633–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaunitz AM. Injectable long-acting contraceptives. Clin Obstet Gynecol. 2001;44:73–91.

Article  CAS  PubMed  Google Scholar 

Swindells S, Siccardi M, Barrett SE, Olsen DB, Grobler JA, Podany AT, Nuermberger E, Kim P, Barry CE, Owen A, Hazuda D, Flexner C. Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges. Int J Tuberc Lung Dis. 2018;22:125–32.

Article  CAS  PubMed  Google Scholar 

FDA. 2023; https://www.fda.gov/drugs/human-immunodeficiency-virus-hiv/fda-approves-cabenuva-and-vocabria-treatment-hiv-1-infection. accessed 13-Feb-2023.

Giliad. 2023; https://www.gilead.com/news-and-press/press-room/press-releases/2021/3/gilead-and-merck-announce-agreement-to-jointly-develop-and-commercialize-longacting-investigational-treatment-combinations-of-lenacapavir-and-islatr. accessed 13-Feb-2023.

Liversidge GG, Cundy KC, Bishop JF, Czekai DA. Surface Modified Drug Nanoparticles. United States Patent. 1992;5:145684.

Google Scholar 

Shi J, Wang D, Tian Y, Wang Z, Gao J, Liu N, Gao X, Zheng A, Zhang H, Xiang M. Comparison of paliperidone palmitate from different crystallization processes and effect on formulations in vitro and in vivo. Pharmaceutics. 2022;14:1094.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kalepu S, Nekkanti V. Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharm Sin B. 2015;5:442–53.

Article  PubMed  PubMed Central  Google Scholar 

Wu L, Zhang J, Watanabe W. Physical and chemical stability of drug nanoparticles. Adv Drug Deliv Rev. 2011;63:456–69.

Article  CAS  PubMed  Google Scholar 

Kesisoglou F, Panmai S, Wu Y. Nanosizing–oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 2007;59:631–44.

Article  CAS  PubMed  Google Scholar 

Malamatari M, Taylor KMG, Malamataris S, Douroumis D, Kachrimanis K. Pharmaceutical nanocrystals: production by wet milling and applications. Drug Discov Today. 2018;23:534–47.

Article  CAS  PubMed  Google Scholar 

Li M, Azad M, Davé R, Bilgili E. Nanomilling of Drugs for Bioavailability Enhancement: A Holistic Formulation-Process Perspective. Pharmaceutics. 2016;8:17.

Article  PubMed  PubMed Central  Google Scholar 

Verma S, Kumar S, Gokhale R, Burgess DJ. Physical stability of nanosuspensions: investigation of the role of stabilizers on Ostwald ripening. Int J Pharm. 2011;406:145–52.

Article  CAS  PubMed  Google Scholar 

Thanh NT, Maclean N, Mahiddine S. Mechanisms of nucleation and growth of nanoparticles in solution. Chem Rev. 2014;114:7610–30.

Article  CAS  PubMed  Google Scholar 

Nyqvist H, Wadsten T. Structure-related variation in epimer ratio and solvent content of bacampicillin hydrochloride. Acta Pharm Suec. 1985;22:215–28.

CAS  PubMed  Google Scholar 

De Cleyn E, Holm R, Van den Mooter G. Shedding a light on the physical stability of suspensions micronised with intensified vibratory milling; A trend observed with decreasing particle size as a function of time. Int J Pharm. 2021;603:120687.

Article  PubMed  Google Scholar 

Joshi V, Dwivedi S, Ward GH. Increase in the specific surface area of budesonide during storage postmicronization. Pharm Res. 2002;19:7–12.

Article  CAS  PubMed  Google Scholar 

Lee RW, Shaw JM, McShane J, Wood RW, Shenoy DB. Particle size reduction. In: Water-insoluble drug formulations, Liu R (editor), Interpharm Press, 2008, Second Edition, chapter 17, pp. 467–99.

Kesteleyn B, Amssoms K, Schepens W, Hache G, Verschueren W, Van De Vreken W, Rombauts K, Meurs G, Sterkens P, Stoops B, Baert L, Austin N, Wegner J, Masungi C, Dierynck I, Lundgren S, Jönsson D, Parkes K, Kalayanov G, Wallberg H, Rosenquist A, Samuelsson B, Van Emelen K, Thuring JW. Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application. Bioorg Med Chem Lett. 2013;23:310–7.

Article  CAS  PubMed  Google Scholar 

Netzsch. 2022. (https://grinding.netzsch.com/en/pharma-cosmetics/wet-grinding), accessed 10-Nov-2022.

WAB. 2022. (https://www.wab-group.com/en/grinding-dispersing/agitator-bead-mills/) , accessed 10-Nov-2022.

留言 (0)

沒有登入
gif